Skip to contentE
Endovia Health Sciences, Inc.
E
EDVAEndovia Health Sciences, Inc. Q4 2017 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$155.70K$155.70Kderived−44.5% vs Q4 2016 Net Income-$101.89K-$101.89KderivedN/M vs Q4 2016 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endovia Health Sciences, Inc. · CIK 1553788 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$58,316−60.9% Operating Incomederived-$107,448N/M Operating Cash Flowderived-$10,036N/M Free Cash Flowderived-$20,112N/M Margins · derivedGross margin37.5%−15.7 pt vs Q4 2016
Operating margin-69.0%−55.7 pt vs Q4 2016
Net margin-65.4%−52.2 pt vs Q4 2016
ended Dec 31, 2017 · filed Apr 2, 2018 · 92 d after period end